Skip to content

Improving Access to Abortion in the Republic of Georgia

Improving Access to Abortion in the Republic of Georgia

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04458558
Enrollment
120
Registered
2020-07-07
Start date
2020-06-30
Completion date
2021-04-01
Last updated
2020-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abortion Early, Pregnancy Related

Brief summary

In the Republic of Georgia, the medical abortion regimen involves three in-person visits. This study aims to pilot and evaluate a simplified medical abortion service delivery model that will reduce the number of in-person visits to only one visit for diagnosis and counseling. Medication will be mailed along with two multi-level pregnancy tests to study participants, who will assess their abortion outcome at home.

Detailed description

This prospective cohort study of patients obtaining medical abortion medications by mail. The study investigators aim to recruit approximately 120 patients for this study across three study sites that have extensive experience providing early medical abortion. Five days after undergoing in-person consultation and necessary exams to assess eligibility for medical abortion, study team will mail study participants medical abortion pills and two multi-level urine pregnancy tests. Medical abortion follow-up will occur at the participant's home approximately two weeks after the initial visit, and the multi-level pregnancy test will be used to assess abortion outcome. At follow-up, study participants will be asked questions about the results of the multi-level pregnancy test, and their experience and feedback about the acceptability of the process. At the conclusion of the study, investigators will interview providers to better undertand their experience with the simplified medical abortion service delivery model.

Interventions

DRUGMifepristone

Participants will receive mifepristone at a preferred address by mail rather than standard care at clinic visit.

Sponsors

Gynuity Health Projects
CollaboratorOTHER
Healthy Life
CollaboratorUNKNOWN
Grand Challenges Canada
CollaboratorOTHER
Center for Information and Counseling on Reproductive Health - Tanadgoma
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Intervention model description

Prospective Cohort

Eligibility

Sex/Gender
FEMALE
Age
16 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Women seeking medical abortion through 58 days gestation * Eligible for medical abortion according to study provider's assessment * Able to receive physical mail * Have access to a phone * Be willing and able to consent to participate in the study * Be willing to follow study procedures

Exclusion criteria

* Not seeking medical abortion * Contraindications to medical abortion

Design outcomes

Primary

MeasureTime frameDescription
Number of participants who report satisfactory experienceDay 14 following initial medical abortion visitNumber of participants who report being satisfied or very satisfied with the simplified medical abortion service delivery model
Number of providers who report satisfactory experienceEnd of the study, month 15Number of providers who report being satisfied or very satisfied with the simplified medical abortion service delivery model

Secondary

MeasureTime frameDescription
Number of particpants with adverse event associated with mailing of medical abortion medicationsUp to 6 weeks after initial medical abortion visitNumber of participants who had a problem (such as delayed and lost packages) receiving medical abortion medications by mail
Number of participants with adverse eventUp to 6 weeks after initial medical abortion visitNumber of participants who had a medical problem that required them to go to the hospital, emergency department or a doctor's office (other than regularly scheduled follow-up visit) since receiving medical abortion pills
Number of participants who refuse to receive medical abortion pills by mailEnd of the study, month 15Number of participants who refuse to receive medical abortion pills by mail during the study period
Cost associated with the simplified medical abortion service delivery modelUp to 6 weeks after initial medical abortion visitCost savings associated with participant travel to the clinic and cost of the standard care at the clinic.
Number of participants with a complete abortion with medication alone and who do not require additional interventions to complete the procedureUp to 6 weeks after initial medical abortion visitNumber of participants who report that their abortion is complete as assessed by the multi-level pregnancy test and medical history.

Countries

Georgia

Contacts

Primary ContactNino Tsereteli, MA
tsereteli_nino@yahoo.com+995 599 158 030
Backup ContactLia Mamatsashvili, MD, MPH
l.mamatsashvili@gmail.com+995 599 930 440

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026